[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-334023-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-334023-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","targeted-hybrid-nanocarriers-as-co-delivery-systems-for-enhanced-cancer-therapy","Targeted Hybrid Nanocarriers as Co-Delivery Systems for Enhanced Cancer Therapy","","Hybrid nanocarriers have gained increasing attention in drug delivery research for their potential to treat, manage, or cure diseases with limited therapeutic options. Cancer remains the second leading global cause of death, driving demand for efficacious and safe formulations. Major challenges in chemotherapy include non-selective uptake, severe adverse effects, and multidrug resistance leading to treatment failure. Targeting hybrid nanocarriers enables co-delivery of two or more chemotherapeutics, supporting synergistic or additive outcomes, and may also serve as safer non-viral gene vectors. An extensive review of these systems is presented, outlining future prospects for metastatic, multidrug-resistant, and poor-prognosis cancers.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/targeted-hybrid-nanocarriers-as-co-delivery-systems-for-enhanced-cancer-therapy/334023/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/targeted-hybrid-nanocarriers-as-co-delivery-systems-for-enhanced-cancer-therapy/334023.png","ImageObject",300,407,{"name":42,"@type":43},"Sage","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are targeted hybrid nanocarriers considered promising for cancer therapy?","Question",{"text":63,"@type":64},"They can be targeted to tumor sites and enable co-delivery of multiple chemotherapeutics, producing synergistic or additive therapeutic effects while improving selectivity.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What limitations of conventional cancer chemotherapy are highlighted?",{"text":68,"@type":64},"Non-selective cellular uptake leads to severe adverse effects, and multidrug resistance can cause treatment failure.",{"name":70,"@type":61,"acceptedAnswer":71},"How might hybrid nanocarriers contribute beyond chemotherapy?",{"text":72,"@type":64},"They may function as non-viral gene vectors, potentially offering higher transfection with improved safety compared with viral vectors.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},334023,1790210174,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":109,"preview_page_count":4},687197207057,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Adv Pharm Bull, 2024, 14(3), 558-573 doi: 10.34172/apb.2024.046  \n[https://apb.tbzmed.ac.ir](https://apb.tbzmed.ac.ir)  \nTUOMSP RESS  \nReview Article  \nTargeted Hybrid Nanocarriers as Co-Delivery Systems for Enhanced Cancer Therapy  \nJoan Onyebuchi Erebor1* ID , Elizabeth Oladoyin Agboluaje2 ID , Ava M. Perkins3 ID , Megha Krishnakumar4, Ndidi Ngwuluka5 ID 1MAFEREB, LLC, 46701 Commerce Center Dr. Plymouth, MI 48170-2475 USA.  \n2 Department of Pharmaceutical and Biomedical Sciences University of Georgia, 250 W. Green Street Athens, Georgia 30602- 5036 USA.  \n3 Department of Pharmacy Practice, College of Pharmacy and Pharmaceutical Sciences, The University of Toledo 3000 Arlington Ave, Toledo, OH 43614-2595 USA.  \n4Catalent Pharma Solutions, 7330 Carroll Road, San Diego, California 92121-2363 USA.  \n5 Department of Pharmaceutics, Faculty of Pharmacy, University of Jos, Pharmaceutical Sciences Gate, Bauchi Rd, 930001, Jos, Plateau State, Nigeria.  \nArticle info  \nArticle History:  \nReceived: April 17, 2023  \nRevised: April 29, 2024  \nAccepted: May 13, 2024  \nepublished: May 15, 2024  \nKeywords:  \nCancer therapy, Hybrid nanocarriers, Co-delivery, Drug delivery, Targeted, Nanoparticles  \nAbstract  \nHybrid nanocarriers have realized a growing interest in drug delivery research because of the potential of being able to treat, manage or cure diseases that previously had limited therapy or cure. Cancer is currently considered the second leading cause of death globally. This makes cancer therapy a major focus in terms of the need for efficacious and safe drug formulations that can be used to reduce the rate of morbidity and mortality globally. The major challenge encountered over the years with cancer chemotherapy is the non-selectivity of anticancer drugs, leading to severe adverse effects in patients. Multidrug resistance has also resulted in treatment failure in cancer chemotherapy over the years. Hybrid nanocarriers can be targeted to the site and offer co-delivery of two or more chemotherapeutics, thus leading to synergistic or additive results. This makes hybrid nanocarriers an extremely attractive type of drug delivery system for cancer therapy. Hybrid nanocarrier systems are also attracting attention as possible non-viral gene vectors that could have a higher level of transfection, and be efficacious, with the added advantage of being safer than viral vectors in clinical settings. An extensive review of various aspects of hybrid nanocarriers was discussed in this paper. It is envisaged that in the future, metastatic cancers, multi-drug resistant cancers, and low prognosis cancers like pancreatic cancers, will have a lasting solution via hybrid nanocarrier formulations with targeted codelivery of therapeutics.  \nIntroduction  \nCancer therapeutics has the major challenge of nonselective cellular uptake for cancer cells in cancer therapy. Over the years, efficacious cancer treatment with low side effects on normal tissues has been quite difficult to achieve. This has resulted in poor prognosis in some types of cancer despite the wide range of cancer treatments currently available. The factors influencing the therapeutic outcome are multiple, including the nature of the disease, the actual stage of the disease, multidrug resistance, the physiological makeup of the human body, and individual human idiosyncrasies. Nanomedicines facilitated a shift from controlled release to a more targeted form of drug delivery with the focus on nanocarriers as possible drug delivery vehicles to various cancers such as very aggressive pancreatic cancer disease with a five-year survival rate of less than 5%, ovarian and breast cancer, to ensure selective, preferential accumulation of larger payloads within tumor  \nsites,1,2 increased efficacy and increased safety with fewer side effects in drug delivery.3 Targeted cancer therapy using nanocarriers has gained traction and the Web of Science recorded almost 8000 peer-reviewed publications in the field of","cbCaij13Gr8gKdny","https://ap.wps.com/l/cbCaij13Gr8gKdny","pdf",1690024,16,"English","# Article info\n## Article History\n## Keywords\n# Abstract\n# Introduction\n## Prevalent cancer treatment methods and their challenges","[{\"question\":\"Why are targeted hybrid nanocarriers considered promising for cancer therapy?\",\"answer\":\"They can be targeted to tumor sites and enable co-delivery of multiple chemotherapeutics, producing synergistic or additive therapeutic effects while improving selectivity.\"},{\"question\":\"What limitations of conventional cancer chemotherapy are highlighted?\",\"answer\":\"Non-selective cellular uptake leads to severe adverse effects, and multidrug resistance can cause treatment failure.\"},{\"question\":\"How might hybrid nanocarriers contribute beyond chemotherapy?\",\"answer\":\"They may function as non-viral gene vectors, potentially offering higher transfection with improved safety compared with viral vectors.\"}]","Targeted Hybrid Nanocarriers as Co-Delivery Systems for Enhanced Cancer Therapy | PDF",1790005031]